Apellis
Apellis is a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing medicines.
At Apellis, we are committed to developing transformative therapies for people living with Geographic Atrophy (GA) by regulating complement, a part of the body’s immune system.
Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases such as GA, where there are currently no treatment options available.
